4SCAR-276

· Shenzhen Geno-Immune Medical Institute

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 4SCAR-276, covering 2020-06-16 to 2020-06-16. Get the full timeline:

Most recent: Clinical Trial Update: Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 [Phase 1, Phase 2]